Filter Results:
(262)
Show Results For
- All HBS Web
(262)
- News (29)
- Research (197)
- Multimedia (2)
- Faculty Publications (103)
Show Results For
- All HBS Web
(262)
- News (29)
- Research (197)
- Multimedia (2)
- Faculty Publications (103)
- September 2010
- Teaching Note
Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)
By: Willy C. Shih
Teaching Note for 611009. View Details
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
Keywords: Competition; Intellectual Property; Advertising; Health Care and Treatment; Brands and Branding; Product Marketing; Pharmaceutical Industry; United States
Bell, David E. "Nopane Advertising Strategy." Harvard Business School Case 893-005, October 1992. (Revised September 1993.)
- 01 Oct 1998
- News
Playing to Win
Seldom, if ever, has global competition been so glamorous, or so passionately beheld. At soccer's World Cup in France this summer, hundreds of thousands of spectators and a cumulative TV audience of 37 billion cheered and wept as 32... View Details
Keywords: Garry Emmons
- 28 Aug 2017
- Research & Ideas
Should Industry Competitors Cooperate More to Solve World Problems?
are persistent issues that in many cases have worsened. "Addressing these issues is critical for the future competitiveness of these industries" In our competitive landscape, ESG efforts are guided... View Details
- March 2009
- Teaching Note
Proteus Biomedical: Making Pigs Fly (TN)
Teaching Note for [809051]. View Details
- 01 Aug 2001
- News
Cleveland Global Alumni Conference a Sold-Out Success
Growth," followed four tracks of inquiry: managing innovation, information technology and competitive strategy, transforming the enterprise, and entrepreneurship. "Ours is an era of organizational experimentation," observed Professor Gary... View Details
- 15 Dec 2024
- News
After Ozempic
these drugs, known as GLP-1 agonists, amounts to so much more than media buzz. In just a few years, they have ignited a wave of change that has transformed Novo Nordisk into Europe’s most valuable public company. The seismic shift is on track to continue reshaping the... View Details
- March 1999 (Revised June 2000)
- Case
Eli Lilly: The Evista Project
By: Steven C. Wheelwright and Matt Verlinden
Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)... View Details
Keywords: Projects; Groups and Teams; Operations; Management Teams; Product Development; Transition; Product Design; Business Startups; Business Plan; Product Launch; Competition; Service Operations; Pharmaceutical Industry
Wheelwright, Steven C., and Matt Verlinden. "Eli Lilly: The Evista Project." Harvard Business School Case 699-016, March 1999. (Revised June 2000.)
- 01 May 2007
- First Look
First Look: May 1, 2007
Casadesus-Masanell and Andres Hervas-Drane Abstract We study competitive interaction between two alternative models of digital content distribution over the Internet: peer-to-peer (p2p) file sharing and centralized client-server... View Details
Keywords: Sean Silverthorne
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
- 06 Aug 2001
- Research & Ideas
Go Global—or No? Can You Make the Case?
the face of a new competitive threat. HBR published comments from four management gurus on what DataClear should do. (See Close Up.) Now it's your turn. We have included an excerpt of the case and a summary of the consultants' advice. But... View Details
Keywords: by Walter Kuemmerle
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
coming of age of biotechnology. The disappearance of "blockbuster" drugs could create new management challenges for pharmaceutical companies. — Gary Pisano The prospect is exhilarating, but the road to this brave new biotech... View Details
- 28 Apr 2009
- First Look
First Look: April 28, 2009
the United States and Germany in particular, and the United States and European Union more generally, suggests that how countries resolve tensions between protecting patients and empowering consumers will impact the international View Details
Keywords: Martha Lagace
- 17 Mar 2009
- First Look
First Look: March 17, 2009
to combat gray markets is to increase internal transfer prices to foreign subsidiaries in order to increase the gray market's cost base. We illustrate that when a gray market competitor is present, the optimal price for internal transfers exceeds marginal cost but... View Details
Keywords: Martha Lagace
- 02 Oct 2000
- Research & Ideas
The Dubious Logic of Global Megamergers
with their mega-deals, you can exploit that fact to improve your own competitive position. For instance, while pharmaceutical players such as Glaxo Wellcome and SmithKline Beecham have made headlines with... View Details
Keywords: by Pankaj Ghemawat & Fariborz Ghadar
- 01 Jan 2002
- News
Raymond V. Gilmartin (MBA '68)
the business world has an important leadership role to play in terms of closing the gap in health and other vital social issues," he says. When Ray Gilmartin joined Merck in June 1994 as president and CEO (he became chairman several months later), it was the first time... View Details
- 06 Mar 2012
- First Look
First Look: March 6
residential real estate and away from more productive investments. Third, the cost of professional investment management is too high, which drains talent from other industries. The financial sector could promote the health and View Details
Keywords: Sean Silverthorne
- 11 Aug 2003
- Research & Ideas
Cheap, Fast, and In Control: How Tech Aids Innovation
what are some of the possible negative consequences of remaining stagnant? Stefan Thomke: Competitive environments and technologies are constantly changing, which creates both wonderful opportunities to innovate and grave threats if we... View Details
Keywords: by Wendy Guild
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
policy debate. Positive aggregate productivity gains are often attributed to within-firm productivity improvement; however, an alternative, less emphasized explanation is between-firm selection and market reallocation, whereby competition... View Details
Keywords: Sean Silverthorne
- 20 May 2013
- Op-Ed
Making America an Industrial Powerhouse Again
competitive global economy, US manufacturing can thrive only if it is at the leading edge of knowledge. History provides some guidelines for making sure the NNMI lives up to its potential: Have a broad agenda: Government-funded research... View Details